A new experimental drug called Lucid-MS has cleared a major regulatory hurdle, moving into Phase 2 clinical trials for progressive multiple sclerosis (MS) after receiving FDA approval. Unlike most existing MS treatments that focus on suppressing the immune system, Lucid-MS takes a different approach: it aims to protect nerve fibers and potentially reverse the myelin breakdown that drives disability in progressive forms of the disease.

The FDA's approval of Quantum BioPharma's Investigational New Drug (IND) application marks a significant moment for patients with primary progressive MS (PPMS) and secondary progressive MS (SPMS), conditions where treatment options remain severely limited. According to market research, the primary progressive MS treatment market is projected to grow from $1.16 billion in 2025 to $1.31 billion by 2026, reflecting the urgent demand for new therapies.

Why Is Progressive MS So Difficult to Treat?

Progressive forms of MS represent a major unmet medical need worldwide. Despite the availability of disease-modifying therapies (DMTs), a substantial proportion of patients with progressive MS remain untreated or continue to experience disability progression. The problem is that most current treatments focus on calming the immune system, but they don't address the underlying nerve damage that accumulates over time.

Lucid-MS works differently. The drug targets an enzyme called protein arginine deiminase 2 (PAD2), which plays a key role in myelin degradation. Myelin is the protective coating around nerve fibers; when it breaks down, nerve signals become disrupted, leading to loss of mobility, sensation, and bladder control. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse myelin breakdown, offering what researchers call a truly disease-modifying approach.

"Progressive MS has long been an area of frustration for neurologists and patients alike, given the paucity of effective interventions. Lucid-MS offers a differentiated approach; it does not suppress the immune system but instead works to preserve myelin integrity and neuronal function," explained Andrzej Chruscinski, M.D., Ph.D., Vice-President of Scientific and Clinical Affairs at Quantum BioPharma.

Andrzej Chruscinski, M.D., Ph.D., Vice-President of Scientific and Clinical Affairs, Quantum BioPharma

What Will the Phase 2 Trial Evaluate?

The Phase 2 clinical trial will be randomized, double-blind, and placebo-controlled, meaning some patients will receive Lucid-MS while others receive a placebo, and neither the patients nor the researchers will know who gets which treatment. The trial will measure both clinical outcomes (like walking ability and disability progression) and radiological measures (imaging findings) to assess whether the drug actually protects nerve tissue and slows disease advancement.

Quantum BioPharma is partnering with a leading global clinical research organization experienced in neurodegenerative diseases to manage the trial. Site selection is already underway, and patient enrollment is expected to begin as soon as possible. The company's Phase 1 trials in healthy participants showed that Lucid-MS was well-tolerated with a favorable safety profile, providing a strong foundation for this next phase of testing.

How Does This Fit Into the Broader MS Research Landscape?

While Lucid-MS represents one innovative approach, MS research is advancing on multiple fronts. In Australia, MS Australia's 2026 Mid-Year Research Grants have funded three cutting-edge projects addressing the community's top priorities: causes and prevention, better treatments, and cell repair and regeneration.

One particularly promising area involves using artificial intelligence (AI) to improve how doctors detect and monitor MS damage in the spinal cord, a part of the nervous system that is often overlooked but profoundly impacts disability. Dr. Tal Koren from the University of Sydney is developing new MRI technology combined with AI to identify spinal cord lesions that standard scans might miss, helping neurologists better understand why some patients experience worsening symptoms even when their brain scans appear normal.

Steps to Understanding Your MS Treatment Options

• Know Your MS Type: Determine whether you have relapsing-remitting MS, primary progressive MS, or secondary progressive MS, as treatment options differ significantly based on disease course.
• Discuss Current Limitations: Talk with your neurologist about whether your current treatment is slowing disability progression, and ask specifically about newer approaches that target nerve protection rather than just immune suppression.
• Stay Informed About Clinical Trials: Ask your healthcare provider whether you might be eligible for emerging clinical trials like Lucid-MS, which could offer access to novel therapies before they become widely available.
• Monitor Spinal Cord Symptoms: Pay attention to changes in walking ability, fatigue, or bladder function, and report these to your neurologist even if brain imaging appears stable, as spinal cord damage may not show up on standard scans.

The global MS therapeutics market is anticipated to reach approximately $38.62 billion by 2030, growing at a compound annual growth rate of 5.93%, reflecting the substantial investment in developing new treatment approaches. This growth underscores the industry's recognition that current therapies, while helpful for many patients, leave significant gaps in care, particularly for those with progressive disease.

"This Phase 2 trial marks an important strategic milestone for Quantum BioPharma and advances our unique Lucid-MS program into the next stage of development. This is not just a regulatory checkpoint; it is a breakthrough moment to try to demonstrate, possibly for the first time, that neuroprotection is achievable," said Zeeshan Saeed, Founder and Chief Executive Officer of Quantum BioPharma.

Zeeshan Saeed, Founder and Chief Executive Officer, Quantum BioPharma

For the millions of people living with progressive MS worldwide who have limited treatment options, the advancement of Lucid-MS into Phase 2 testing represents a meaningful step forward. The trial will provide critical data on whether targeting myelin protection and nerve preservation can slow or even reverse disability progression, potentially transforming how clinicians approach this challenging disease.